Reuters -- Sanofi-Aventis’s diabetes drug Lantus may increase the risk of cancer, according to European studies involving some 300,000 insulin-treated patients, prompting a call from experts for more research.
Reuters -- Sanofi-Aventis’s diabetes drug Lantus may increase the risk of cancer, according to European studies involving some 300,000 insulin-treated patients, prompting a call from experts for more research.
